SurModics acquires drug delivery assets of PR Pharmaceuticals



The earliest evidence of a nuclear family, dating back to the Stone Age, has been uncovered by an international team of researchers, including experts from the University of Bristol. The researchers dated remains from four multiple burials discovered in Germany in 2005.  The 4,600-year-old graves contained groups of adults and children buried facing each

Full Post: World’s earliest nuclear family found

SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.

SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the successful achievement of certain milestones. The acquisition is expected to be accretive to SurModics’ fiscal 2009 earnings, excluding any one-time charges related to the acquisition.

Anticipated Acquisition Benefits

  • Broadens SurModics’ proprietary technology portfolio in systemic drug delivery, including protein delivery
  • Enables delivery of injectable microparticles through smaller gauge needles
  • Expands SurModics’ customer base to incorporate several new pharmaceutical and biotech companies
  • Immediately adds new sources of revenue and is expected to be accretive to SurModics fiscal 2009 earnings

“The proprietary technologies and existing business we are acquiring from PR Pharmaceuticals are a perfect fit for SurModics,” said Bruce Barclay, president and CEO of SurModics. “The proprietary technologies complement and enhance the existing portfolio of drug delivery capabilities available from SurModics and Brookwood. A broader toolkit for protein delivery and the ability to use smaller gauge needles for microparticle injections make an even more compelling offering for both current and future SurModics customers. The multiple customer development programs we are assuming in this transaction are a strong fit with the diversified portfolio of customer projects at Brookwood and will further leverage the investment we are making in cGMP manufacturing facilities in Birmingham. Further, with the addition of these new technologies, SurModics is poised to drive customer programs and long-term revenue even more effectively.”

The proprietary technologies acquired from PR Pharmaceuticals have broad applicability and address key needs, enabling the delivery of injectable drugs, including proteins, using biodegradable microparticles through smaller diameter needles compared to competing technologies. The use of smaller diameter needles for microparticle injection is particularly relevant in ophthalmology applications. Also, the use of smaller needles is an advantage in many other applications requiring subcutaneous or intra-muscular injections, and in particular where patient self-administration is desired. Proteins and other large molecule therapeutics are of strategic interest to many biotechnology and pharmaceutical companies, but pose significant challenges for drug delivery. The PR Pharmaceuticals technologies will complement those of SurModics and its Brookwood Pharmaceuticals business unit and broaden the overall technology portfolio for the benefit of current and future customer projects.

In addition to the intellectual property being acquired, SurModics will be assuming responsibility for several customer-paid development projects currently in progress with pharmaceutical and biotechnology companies, including Jerini Ophthalmic. Finally, SurModics will be the paid development partner for PR Pharmaceuticals’ proprietary product called InsuLAR™, a once-a-week sustained release formulation of basal insulin for the diabetes marketplace. The market for injectable basal insulin is estimated at approximately $4 billion worldwide.

“We are pleased to consummate this important transaction, and look forward to a long and successful association with SurModics,” said Steve R. Howe, chairman and CEO of PR Pharmaceuticals. “First, we along with Brookwood are committed to providing a smooth transition for current PR Pharmaceuticals customers to Brookwood. Second, the transaction will significantly advance the development of InsuLAR. Collaboration with the technical team and the cGMP manufacturing infrastructure at Brookwood will help ensure successful development and commercialization of InsuLAR as well as provide for a smooth transition for current PR Pharmaceuticals customers. Third, continuation by SurModics of the multiple customer development programs allows PR Pharmaceuticals to focus on developing our own internal programs, products and technologies. While our immediate focus is commercialization of InsuLAR, we anticipate working with SurModics on other collaborative programs in the future.”

“Brookwood Pharmaceuticals gains several attractive assets by virtue of this transaction, which strengthens our portfolio of drug delivery technologies and will greatly benefit our customer development programs,” said Arthur J. Tipton, Ph.D., vice president of SurModics and president of Brookwood. “In particular, the ability to use smaller gauge needles for injections is of significant interest to customers in ophthalmology and several other clinical areas. In addition, partnering with PR Pharmaceuticals on the development of InsuLAR adds another promising development program in diabetes to our broad portfolio of customer programs. Today, PR Pharmaceuticals is already a customer of Brookwood for biodegradable polymer, which it uses in support of current development programs. We look forward to aiding PR Pharmaceuticals in the manufacturing scale-up and in the production of both clinical trial materials and final product for InsuLAR.”

“The combined drug delivery expertise of SurModics, Brookwood, and PR Pharmaceuticals is exceptional,” said Anthony P. Adamis, M.D., president and CEO of Jerini Ophthalmic, Inc. “We are very pleased to be working together and look forward to our continued relationship.”

http://www.surmodics.com

Link




Endo Pharmaceuticals and Indevus Pharmaceuticals, Inc. announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00

Full Post: Endo Pharmaceuticals to acquire Indevus Pharmaceuticals



Roche and Memory Pharmaceuticals has announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million. Memory Pharmaceuticals develops innovative drug candidates for the treatment of debilitating central nervous system (CNS)

Full Post: Roche to acquire Memory Pharmaceuticals



Gel Technologies Ltd today announced the successful completion of an investment round of $9 million. The funding will be used to accelerate Sol-Gel’s robust pipeline of innovative topical products for the dermatology market. The company’s pipeline includes a new generation of anti-acne kits that target the $1 billion acne therapy market. “Even in the current

Full Post: Gel Technologies raises $9 million



AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals’ proprietary nebulized formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for pediatric asthma and is currently in Phase III clinical development. UDB has the potential to be nebulized

Full Post: AstraZeneca and MAP Pharmaceuticals announce collaboration on Unit Dose Budesonide



Covidien has announced that it is launching a new and improved Magellan Safety Hypodermic Needle. The development of the new design, which gives clinicians more control and smoother activation of the safety shield, reflects Covidien’s continued commitment to improving healthcare worker safety. “We are transitioning to the new and improved Magellan Safety Needle technology as

Full Post: Launch of new safety hypodermic needle